If a vaccine engineered to specifically provide protection against the Omicron variant of COVID-19, whether or not it additionally protects against other variants of SARS-CoV-2, is released for public use in the US, regardless of whether its use is restricted to particular population segments, before April 1, 2022, 12:00:00 AM ET, this market will resolve to “Yes.” Otherwise this market will resolve to “No”. The source used to resolve this market will be official information released by the FDA (https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization) and/or other official information from the government of the United States of America. Note, this market is only for a vaccine’s availability in the United States, and does not cover any vaccine’s availability in any other country.